Role of pregnane X receptor in chemotherapeutic treatment Wei ZhuoLei HuLan Fan Review Article 03 June 2014 Pages: 217 - 227
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer N. MasudaK. HigakiM. Toi Original Article 29 May 2014 Pages: 229 - 238
Cimetidine attenuates vinorelbine-induced phlebitis in mice by militating E-selectin expression Zhuo WangLijuan MaDingfeng Su Original Article 31 May 2014 Pages: 239 - 247
Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity Hitoshi IshiguroTakashi KawaharaHiroshi Miyamoto Original Article 01 June 2014 Pages: 249 - 255
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors Ruth PlummerPeter StephensMario Campone Original Article Open access 01 June 2014 Pages: 257 - 265
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment David SchnellSusanne BuschkeRüdiger Koenen Original Article Open access 07 June 2014 Pages: 267 - 275
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer Hee Kyung AhnMinkyu JungEun Kyung Cho Original Article Open access 07 June 2014 Pages: 277 - 282
Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia Shu-mei WangLu-lu SunGuo-liang Zhang Original Article 08 June 2014 Pages: 283 - 289
Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine Jaideep V. ThottasseryVijaya SambandamWilliam B. Parker Original Article 08 June 2014 Pages: 291 - 302
Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia Bingnan ZhangJean BologniaNikolai Podoltsev Original Article 08 June 2014 Pages: 303 - 307
Supplementation of fish oil augments efficacy and attenuates toxicity of 5-fluorouracil in 1,2-dimethylhydrazine dihydrochloride/dextran sulfate sodium-induced colon carcinogenesis Isha RaniKim VaipheiNavneet Agnihotri Original Article 11 June 2014 Pages: 309 - 322
Circulating biomarkers in hepatocellular carcinoma Karen L. MorrisJonathan D. TugwoodCaroline Dive Original Article 13 June 2014 Pages: 323 - 332
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) O. KatopodisJ. SouglakosV. Georgoulias Original Article 15 June 2014 Pages: 333 - 340
Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects Narayana I. NarasimhanDavid J. DorerDaryl Sonnichsen Original Article 17 June 2014 Pages: 341 - 348
Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients Per Hartvig HonoréSigrid Jóhansdóttir JoensenAnders Mellemgaard Original Article 17 June 2014 Pages: 349 - 357
Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies Rahul AggarwalJennifer GrabowskyPamela Munster Original Article 17 June 2014 Pages: 359 - 365
Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli l-asparaginase preparation (MC0609) in Beagle dog Stephan BorghorstGeorg HempelJoachim Baumgart Original Article 17 June 2014 Pages: 367 - 378
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) T. DragovichD. LaheruD. D. Von Hoff Original Article 18 June 2014 Pages: 379 - 387
Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer Jun CaoJian ZhangXichun Hu Original Article 18 June 2014 Pages: 389 - 398
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates Dan LuSandhya GirishJin Yan Jin Original Article Open access 18 June 2014 Pages: 399 - 410
Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers M. Naveed ShaikRobert R. LaBadieWendy J. Levin Original Article 19 June 2014 Pages: 411 - 418
A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies Andrea Wang-GillamNilay ThakkarJoel Picus Clinical Trial Report Open access 11 June 2014 Pages: 419 - 426
In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia Aleksandar RadujkovicThomas LuftJulian Topaly Short Communication 20 July 2014 Pages: 427 - 432
Gastric cancer with para-aortic lymph node metastases: do not miss a chance of cure! Daniele MarrelliMaria Antonietta MazzeiFranco Roviello Letter to the Editor 03 June 2014 Pages: 433 - 434
Gastric cancer with para-aortic lymph nodes metastasis: curable dissection possible but be cautiously selected Tianshu LiuYihong SunYan Wang Letter to the Editor 15 July 2014 Pages: 435 - 436